EPCAM and prostate carcinoma: EpCAM is a membrane glycoprotein highly expressed in the majority of carcinomas; accordingly, this is the first and only clinically validated U.S. Food and Drug Administration (FDA)-cleared blood test for detecting CTCs in patients with metastatic breast, colorectal, or prostate cancer [19].